Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2018-02-07FDA Approved: ZYTIGA — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for ZYTIGA (abiraterone acetate) from Janssen Biotech, Inc., indicating an approved update to the pr…
-
FDA approval · 2018-02-02FDA Approved: XOFIGO — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
The FDA approved a supplemental application for XOFIGO (radium-223 dichloride) by Bayer HealthCare Pharmaceuticals Inc., signaling an expand…
-
CLINICAL_TRIALS trial_result · 2018-01-16Clinical Trial Update: Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer [Phase 2]
Phase 2 trial evaluating pasireotide with or without everolimus in castration-resistant, chemotherapy-naive prostate cancer; the study is te…
-
FDA approval · 2018-01-09FDA Approved: JEVTANA — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved a supplemental application for JEVTANA (cabazitaxel) filed by Sanofi-Aventis U.S. LLC.
-
CLINICAL_TRIALS trial_result · 2017-12-14Clinical Trial Update: CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy [Phase 2]
Phase 2 trial evaluating cabazitaxel with or without prednisone in metastatic castration-resistant prostate cancer after prior docetaxel the…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-12-06Clinical Trial Update: Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating the combination of alisertib with abiraterone acetate and prednisone in hormone-resistant prostate cance…
-
CLINICAL_TRIALS trial_result · 2017-12-06Clinical Trial Update: Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer [Phase 2]
Phase 2 clinical trial comparing cabazitaxel against abiraterone acetate or enzalutamide in patients with poor-prognosis metastatic castrati…
-
CLINICAL_TRIALS trial_result · 2017-11-29Clinical Trial Update: Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate [Phase 2]
Phase 2 trial comparing Docetaxel to Abiraterone as first-line therapy in metastatic castration-resistant prostate cancer with intraductal p…
-
CLINICAL_TRIALS trial_result · 2017-11-20Clinical Trial Update: Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) [Phase 2]
A Phase 2 trial comparing the sequence of first-line docetaxel/prednisone followed by cabazitaxel/prednisone versus the reverse order in men…
-
CLINICAL_TRIALS trial_result · 2017-11-20Clinical Trial Update: A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 1]
Phase 1 study of ZEN003694 in metastatic castration-resistant prostate cancer has completed.
-
CLINICAL_TRIALS withdrawal · 2017-10-30Clinical Trial Update: Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer [Phase 2]
A Phase 2 trial evaluating sipuleucel-T (Provenge) followed by docetaxel in castration-resistant prostate cancer has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2017-10-23Clinical Trial Update: Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate Cancer [Phase 1]
This document provides an update on a completed Phase 1 study of abiraterone acetate in castration-resistant prostate cancer.
-
FDA approval · 2017-09-14FDA Approved: JEVTANA — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for JEVTANA (cabazitaxel) submitted by Sanofi-Aventis U.S. LLC.
-
CLINICAL_TRIALS trial_result · 2017-08-31Clinical Trial Update: Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer [Phase 2]
Phase 2 trial of orteronel for metastatic castration-resistant prostate cancer was terminated, with results posted.
-
CLINICAL_TRIALS trial_result · 2017-08-24Clinical Trial Update: Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer [Phase 1]
Phase 1 trial evaluating the combination of Sipuleucel-T and Ipilimumab for advanced or castration-resistant prostate cancer has completed.
-
CLINICAL_TRIALS research · 2017-08-08Clinical Trial Update: Plasma and Urine Samples From Patients With Hormone-Refractory Prostate Cancer Enrolled on Clinical Trials CALGB-9480 or CALGB-9583
This clinical trial update notes that plasma and urine samples were collected from patients with hormone-refractory prostate cancer enrolled…
-
FDA approval · 2017-07-24FDA Approved: XTANDI — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for XTANDI (enzalutamide) submitted by Astellas Pharma US, Inc.
-
CLINICAL_TRIALS trial_result · 2017-07-21Clinical Trial Update: Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer [Phase 1]
A Phase I trial evaluating cabazitaxel, mitoxantrone, and prednisone in metastatic castration-resistant prostate cancer has completed enroll…
-
CLINICAL_TRIALS trial_result · 2017-07-19Clinical Trial Update: NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis [Phase 2]
Phase 2 trial update investigating NaF PET/CT imaging to assess treatment response to TAK-700 in castration-resistant prostate cancer with b…
-
CLINICAL_TRIALS trial_result · 2017-07-11Clinical Trial Update: Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer [Phase 1, Phase 2]
AEZS-108, a doxorubicin-GnRH agonist conjugate, completed Phase 1/2 testing in metastatic hormone-resistant prostate cancer. The trial was c…
-
CLINICAL_TRIALS trial_result · 2017-07-11Clinical Trial Update: Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer [Phase 1]
Phase 1 clinical trial results for ONC1-0013B in progressive metastatic castration-resistant prostate cancer report safety, tolerability, an…
-
CLINICAL_TRIALS trial_result · 2017-07-07Clinical Trial Update: Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer [Phase 2]
A Phase 2 clinical trial evaluating abiraterone acetate plus prednisone with or without dasatinib for metastatic castration-resistant prosta…
-
CLINICAL_TRIALS trial_result · 2017-07-02Clinical Trial Update: A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC) [Phase 2]
Phase IIa randomized study evaluating radium-223 dichloride with abiraterone acetate or enzalutamide in metastatic castration-resistant pros…
-
CLINICAL_TRIALS trial_result · 2017-06-26Clinical Trial Update: Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates [Phase 1]
Phase 1 trial evaluated pharmacokinetic interactions between MDV3100 (enzalutamide) and a substrate cocktail. The study, conducted in castra…
-
CLINICAL_TRIALS trial_result · 2017-06-14Clinical Trial Update: Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer [Phase 2]
Phase 2 trial results for combining abiraterone acetate with dutasteride in metastatic castration-resistant prostate cancer have been posted…